Understanding and modulating mammalian-microbial communication for improved human health

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 559-580

  Mani, Sridhar ^a   Boelsterli, Urs A ^b   Redinbo, Matthew R ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Drug discovery; Irinotecan; Microbiome; NSAIDs; glucuronidase

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BACTERIAL ENZYME; BETA GLUCURONIDASE; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; XENOBIOTIC AGENT;

BACTERIAL CELL; BIOTRANSFORMATION; COMMENSAL; DRUG MECHANISM; DYSBIOSIS; ENTEROPATHY; HEALTH STATUS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; INFLAMMATION; INTESTINE FLORA; METABOLISM; METABOLITE; MICROBIOME; MICROFLORA; MOLECULAR RECOGNITION; NEUROBIOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CAMPTOTHECIN; DISEASE MODELS, ANIMAL; ENTERITIS; EOSINOPHILIA; GASTRITIS; GASTROINTESTINAL TRACT; GLUCURONIDASE; HUMANS; LIPOPOLYSACCHARIDES; MAMMALS; MICROBIOTA;

EID: 84891848483     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-140007     Document Type: Review

References (159)

1. Escherich T. 1885. Die darmbakterien des neugeborenen und sauglings. Fortschr. Med. 3:447-547
2. Fuller AT. 1937. Is p-aminobenzenesulphonamide the active agent in prontosil therapy? Lancet 229:194-98
3. Bachrach WH. 1988. Sulfasalazine: I. An historical perspective. Am. J. Gastroenterol. 83:487-96
4. Svartz N. 1988. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am. J. Gastroenterol. 83:497-503
5. Scheline RR. 1973. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev. 25:451-523
6. Project HM. 2012. Structure, function and diversity of the healthy humanmicrobiome. Nature 486:207-14
7. Hooper LV, Gordon JI. 2001. Commensal host-bacterial relationships in the gut. Science 292:1115-18
8. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. 2001. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291:881-84
9. Tseng TT, Tyler BM, Setubal JC. 2009. Protein secretion systems in bacterial-host associations, and their description in the Gene Ontology. BMC Microbiol. 9(Suppl. 1):S2
10. Wostmann BS, Larkin C, Moriarty A, Bruckner-Kardoss E. 1983. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab. Anim. Sci. 33:46-50
11. Stappenbeck TS, Hooper LV, Gordon JI. 2002. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc. Natl. Acad. Sci. USA 99:15451-55
12. Štěpánková R, Kovář û F, Kruml J. 1980. Lymphatic tissue of the intestinal tract of germfree and conventional rabbits. Folia Microbiol. 25:491-95
13. Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. 1997. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J. Immunol. 159:1739-45
14. Talham GL, Jiang HQ, Bos NA, Cebra JJ. 1999. Segmented filamentous bacteria are potent stimuli of a physiologically normal state of the murine gut mucosal immune system. Infect. Immun. 67:1992-2000
15. Lanning D, Sethupathi P, Rhee KJ, Zhai SK, Knight KL. 2000. Intestinal microflora and diversification of the rabbit antibody repertoire. J. Immunol. 165:2012-19
16. Rhee KJ, Sethupathi P, Driks A, Lanning DK, Knight KL. 2004. Role of commensal bacteria in development of gut-associated lymphoid tissues and preimmune antibody repertoire. J. Immunol. 172:1118-24
17. Sun Z, Kong J, Hu S, Kong W, Lu W, Liu W. 2013. Characterization of a S-layer protein from Lactobacillus crispatus K313 and the domains responsible for binding to cellwall and adherence to collagen. Appl. Microbiol. Biotechnol. 97:1941-52
18. Jacchieri SG, Torquato R, Brentani RR. 2003. Structural study of binding of flagellin by Toll-like receptor 5. J. Bacteriol. 185:4243-47
19. Lamkanfi M, Dixit VM. 2009. Inflammasomes: guardians of cytosolic sanctity. Immunol. Rev. 227:95-105
20. Baron MJ, Kasper DL. 2005. Anchors away: contribution of a glycolipid anchor to bacterial invasion of host cells. J. Clin. Investig. 115:2325-27
21. Wiese A, Seydel U. 1999. Interaction of peptides and proteins with bacterial surface glycolipids: a comparison of glycosphingolipids and lipopolysaccharides. J. Ind. Microbiol. Biotechnol. 23:414-24
22. Delaloye J, Calandra T. 2013. Host innate immune responses to microbial pathogens. Curr. Vasc. Pharmacol. 11:123-32
23. Ivanov D, Emonet C, Foata F, Affolter M, Delley M, et al. 2006. A serpin from the gut bacterium Bifidobacterium longum inhibits eukaryotic elastase-like serine proteases. J. Biol. Chem. 281:17246-52
24. Mitsuma T, Odajima H, Momiyama Z, Watanabe K, Masuguchi M, et al. 2008. Enhancement of gene expression by a peptide p(CHWPR) produced by Bifidobacterium lactis BB-12. Microbiol. Immunol. 52:144-55
25. Sanchez B, Urdaci MC, Margolles A. 2010. Extracellular proteins secreted by probiotic bacteria as mediators of effects that promote mucosa-bacteria interactions. Microbiology 156:3232-42
26. Rath CM, Dorrestein PC. 2012. The bacterial chemical repertoire mediates metabolic exchange within gut microbiomes. Curr. Opin. Microbiol. 15:147-54
27. Henderson JP, Crowley JR, Pinkner JS, Walker JN, Tsukayama P, et al. 2009. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathog. 5:e1000305
28. Vassiliadis G, Destoumieux-Garzon D, Lombard C, Rebuffat S, Peduzzi J. 2010. Isolation and characterization of two members of the siderophore-microcin family, microcins M and H47. Antimicrob. Agents Chemother. 54:288-97
29. Claus SP, Ellero SL, Berger B, Krause L, Bruttin A, et al. 2011. Colonization-induced host-gut microbial metabolic interaction. mBio 2:e00271-10
30. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, et al. 2012. Host-gut microbiota metabolic interactions. Science 336:1262-67
31. Hughes DT, Terekhova DA, Liou L, Hovde CJ, Sahl JW, et al. 2010. Chemical sensing in mammalian host-bacterial commensal associations. Proc. Natl. Acad. Sci. USA 107:9831-36
32. Hughes DT, Sperandio V. 2008. Inter-kingdom signalling: communication between bacteria and their hosts. Nat. Rev. Microbiol. 6:111-20
33. Wallace B, Wang H, Lane KT, Scoot JE, Orans J, et al. 2010. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330:831-35
34. Maurice CF, Haiser HJ, Turnbaugh PJ. 2013. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152:39-50
35. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, et al. 2009. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl. Acad. Sci. USA 106:3698-703
36. Saad R, Rizkallah MR, Aziz RK. 2012. Gut pharmacomicrobiomics: the tip of an iceberg of complex interactions between drugs and gut-associated microbes. Gut Pathog. 4:16
37. Nicholson JK, Holmes E, Wilson ID. 2005. Gut microorganisms, mammalian metabolism and personalized health care. Nat. Rev. Microbiol. 3:431-38
38. Meinl W, Sczesny S, Brigelius-Flohe R, Blaut M, Glatt H. 2009. Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic- metabolizing enzymes in the rat. Drug Metab. Dispos. 37:1179-86
39. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, et al. 2011. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 6:e25482
40. Stecher B, Denzler R, Maier L, Bernet F, Sanders MJ, et al. 2012. Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc. Natl. Acad. Sci. USA 109:1269-74
41. Fischer LJ, Green MD, Harman AW. 1985. Studies on the fate of the glutathione and cysteine conjugates of acetaminophen in mice. Drug Metab. Dispos. 13:121-26
42. Mikov M. 1994. The metabolism of drugs by the gut flora. Eur. J. Drug Metab. Pharmacokinet. 19:201-7
43. Bolca S, Possemiers S, Herregat A, Huybrechts I, Heyerick A, et al. 2007. Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J. Nutr. 137:2242-46
44. Bolca S, Possemiers S, Maervoet V, Huybrechts I, Heyerick A, et al. 2007. Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women. Br. J. Nutr. 98:950-59
45. de Witte P, Lemli L. 1990. The metabolism of anthranoid laxatives. Hepatogastroenterology 37:601-5
46. van Gorkom BA, de Vries EG, Karrenbeld A, Kleibeuker JH. 1999. Review article: anthranoid laxatives and their potential carcinogenic effects. Aliment. Pharmacol. Ther. 13:443-52
47. Okuda H, Ogura K, Kato A, Takubo H, Watabe T. 1998. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J. Pharmacol. Exp. Ther. 287:791-99
48. Peppercorn MA, Goldman P. 1973. Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology 64:240-45
49. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. 2008. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int. J. Pharm. 363:1-25
50. Holt R. 1967. The bacterial degradation of chloramphenicol. Lancet 289:1259-60
51. Bindels LB, Porporato P, Dewulf EM, Verrax J, Neyrinck AM, et al. 2012. Gut microbiota-derived propionate reduces cancer cell proliferation in the liver. Br. J. Cancer 107:1337-44
52. Vipperla K, O'Keefe SJ. 2012. The microbiota and its metabolites in colonic mucosal health and cancer risk. Nutr. Clin. Pract. 27:624-35
53. Ray K. 2012. Gut microbiota: Colorectal cancer-driven by inflammation and gut bacteria? Nat. Rev. Gastroenterol. Hepatol. 9:558
54. Pacheco AR, Curtis MM, Ritchie JM, Munera D, Waldor MK, et al. 2012. Fucose sensing regulates bacterial intestinal colonization. Nature 492:113-17
55. Bucki R, Byfield FJ, Kulakowska A, McCormick ME, Drozdowski W, et al. 2008. Extracellular gelsolin binds lipoteichoic acid and modulates cellular response to proinflammatory bacterial wall components. J. Immunol. 181:4936-44
56. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. 1999. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J. Biol. Chem. 274:10689-92
57. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, et al. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:3749-52
58. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085-88
59. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, et al. 1999. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189:615-25
60. Round JL, Lee SM, Li J, Tran G, Jabri B, et al. 2011. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332:974-77
61. Wang Q, McLoughlin RM, Cobb BA, Charrel-Dennis M, Zaleski KJ, et al. 2006. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J. Exp. Med. 203:2853-63
62. Carvalho FA, Koren O, Goodrich JK, Johansson ME, Nalbantoglu I, et al. 2012. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe 12:139-52
63. Wilson RH, Maruoka S, Whitehead GS, Foley JF, Flake GP, et al. 2012. The Toll-like receptor 5 ligand flagellin promotes asthma by priming allergic responses to indoor allergens. Nat. Med. 18:1705-10
64. Yan D, Wang X, Luo L, Cao X, Ge B. 2012. Inhibition of TLRsignaling by a bacterial protein containing immunoreceptor tyrosine-based inhibitory motifs. Nat. Immunol. 13:1063-71
65. Kelly D, Campbell JI, King TP, Grant G, Jansson EA, et al. 2004. Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-γand Rel A. Nat. Immunol. 5:104-12
66. Klose CS, Kiss EA, Schwierzeck V, Ebert K, Hoyler T, et al. 2013. A T-bet gradient controls the fate and function of CCR6-RORγt+ innate lymphoid cells. Nature 494:261-65
67. Renga B, Mencarelli A, Cipriani S, D'Amore C, Carino A, et al. 2013. The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation. PLoS ONE 8:e54472
68. Kidani Y, Bensinger SJ. 2012. Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity. Immunol. Rev. 249:72-83
69. Monteleone I, MacDonald TT, Pallone F, Monteleone G. 2012. The aryl hydrocarbon receptor in inflammatory bowel disease: linking the environment to disease pathogenesis. Curr. Opin. Gastroenterol. 28:310-13
70. Qiu J, Heller JJ, Guo X, Chen ZM, Fish K, et al. 2012. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 36:92-104
71. Tilg H. 2012. Diet and intestinal immunity. N. Engl. J. Med. 366:181-83
72. Shenderov BA. 2012. Gut indigenous microbiota and epigenetics. Microb. Ecol. Health Dis. 23:17195
73. Wells JM, Rossi O, Meijerink M, van Baarlen P. 2011. Epithelial crosstalk at the microbiota-mucosal interface. Proc. Natl. Acad. Sci. USA 108:4607-14
74. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, et al. 2012. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathog. 8:e1002995
75. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, et al. 2013. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368:407-15
76. Damman CJ, Miller SI, Surawicz CM, Zisman TL. 2012. The microbiome and inflammatory bowel disease: Is there a therapeutic role for fecal microbiota transplantation? Am. J. Gastroenterol. 107:1452-59
77. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, et al. 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 105:16731-36
78. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, et al. 2011. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331:337-41
79. Chiba T, Seno H. 2011. Indigenous Clostridium species regulate systemic immune responses by induction of colonic regulatory T cells. Gastroenterology 141:1114-16
80. Nagano Y, Itoh K, Honda K. 2012. The induction of Treg cells by gut-indigenous Clostridium. Curr. Opin. Immunol. 24:392-97
81. Round JL, Mazmanian SK. 2010. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc. Natl. Acad. Sci. USA 107:12204-9
82. Kumar S, Bansal A, Chakrabarti A, Singhi S. 2013. Evaluation of efficacy of probiotics in prevention of Candida colonization in a PICU-a randomized controlled trial. Crit. Care Med. 41:565-72
83. Lebeer S, Vanderleyden J, De Keersmaecker SC. 2010. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat. Rev. Microbiol. 8:171-84
84. van Baarlen P, Wells JM, Kleerebezem M. 2013. Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends Immunol. 34:208-15
85. Rossi M, Klein K, Johnson DW, Campbell KL. 2012. Pre-, pro-, and synbiotics: Do they have a role in reducing uremic toxins? A systematic review and meta-analysis. Int. J. Nephrol. 2012:673631
86. Steidler L. 2003. Genetically engineered probiotics. Best Pract. Res. Clin. Gastroenterol. 17:861-76
87. Motta JP, Bermúdez-Humarán LG, Deraison C, Martin L, Rolland C, et al. 2012. Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci. Transl. Med. 4:158ra44
88. Mohamadzadeh M, Pfeiler EA, Brown JB, Zadeh M, Gramarossa M, et al. 2011. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl. Acad. Sci. USA 108(Suppl. 1):4623-30
89. Khazaie K, Zadeh M, Khan MW, Bere P, Gounari F, et al. 2012. Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl. Acad. Sci. USA 109:10462-67
90. Grubman A, Phillips A, Thibonnier M, Kaparakis-Liaskos M, Johnson C, et al. 2010. Vitamin B6 is required for full motility and virulence in Helicobacter pylori. mBio 1(3):e00112-10
91. Leblanc JG, Milani C, de Giori GS, Sesma F, van Sinderen D, Ventura M. 2013. Bacteria as vitamin suppliers to their host: a gut microbiota perspective. Curr. Opin. Biotechnol. 24:160-68
92. Buckenhüskes HJ. 1993. Selection criteria for lactic acid bacteria to be used as starter cultures for various food commodities. FEMS Microbiol. Rev. 12:253-71
93. Gracey M, Suharjono, Sunoto, Stone DE. 1973. Microbial contamination of the gut: another feature of malnutrition. Am. J. Clin. Nutr. 26:1170-74
94. Smith MI, Yatsunenko T, Manary MJ, Trehan I, Mkakosya R, et al. 2013. Gutmicrobiomes of Malawian twin pairs discordant for kwashiorkor. Science 339:548-54
95. Arbuckle RB, Huber SL, Zacker C. 2000. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist 5:250-59
96. Arnold RJ, Gabrail N, Raut M, Kim R, Sung JC, Zhou Y. 2005. Clinical implications of chemotherapyinduced diarrhea in patients with cancer. J. Support. Oncol. 3:227-32
97. Richardson G, Dobish R. 2007. Chemotherapy induced diarrhea. J. Oncol. Pharm. Pract. 13:181-98
98. Cherny NI. 2008. Evaluation and management of treatment-related diarrhea in patients with advanced cancer: a review. J. Pain Symptom Manag. 36:413-23
99. Dranitsaris G, Maroun J, Shah A. 2005. Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea. Can. J. Gastroenterol. 19:83-87
100. Dranitsaris G, Maroun J, Shah A. 2005. Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Support. Care Cancer 13:318-24
101. Benson AB III, Ajani JA, Catalano RB, Engelking C, Kornblau SM, et al. 2004. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol. 22:2918-26
102. Stein A, Voigt W, Jordan K. 2010. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther. Adv. Med. Oncol. 2:51-63
103. Field M. 2003. Intestinal ion transport and the pathophysiology of diarrhea. J. Clin. Investig. 111:931-43
104. Rothenberg ML, Meropol NJ, Poplin EA, Van Cutsem E, Wadler S. 2001. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19:3801-7
105. Hebbar M, Ychou M, Ducreux M. 2009. Current place of high-dose irinotecan chemotherapy in patients with metastatic colorectal cancer. J. Cancer Res. Clin. Oncol. 135:749-52
106. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. 1994. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54:3723-25
107. Araki E, Ishikawa M, Iigo M, Koide T, Itabashi M, Hoshi A. 1993. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res. 84:697-702
108. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, et al. 2001. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7:2182-94
109. Hryniuk W. 1988. The importance of dose intensity in the outcome of chemotherapy. Important Adv. Oncol. 1988:121-41
110. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, et al. 1994. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J. Natl. Cancer Inst. 86:446-49
111. Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, et al. 2004. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat. Rev. 30:555-62
112. Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP. 2001. Control of irinotecaninduced diarrhea by octreotide after loperamide failure. Support. Care Cancer 9:258-60
113. Meropol NJ, Blumenson LE, Creaven PJ. 1998. Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. Am. J. Clin. Oncol. 21:135-38
114. Rosenoff S. 2004. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide longacting formulation in cancer patients: 11 case studies. Support. Care Cancer 12:561-70
115. de Jong FA, Kehrer DF, Mathijssen RH, Creemers GJ, de Bruijn P, et al. 2006. Prophylaxis of irinotecaninduced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. Oncologist 11:944-54
116. Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, et al. 2001. Modulation of irinotecaninduced diarrhea by cotreatment with neomycin in cancer patients. Clin. Cancer Res. 7:1136-41
117. Flieger D, Klassert C, Hainke S, Keller R, Kleinschmidt R, Fischbach W. 2007. Phase II clinical trial for prevention of delayed diarrhea with cholestyramine/levofloxacin in the second-line treatment with irinotecan biweekly in patients with metastatic colorectal carcinoma. Oncology 72:10-16
118. Schmittel A, Jahnke K, Thiel E, Keilholz U. 2004. Neomycin as secondary prophylaxis for irinotecaninduced diarrhea. Ann. Oncol. 15:1296
119. Zhao J, Huang L, Belmar N, Buelow R, Fong T. 2004. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin. Cancer Res. 10:2851-59
120. Ohdo S, Makinosumi T, Ishizaki T, Yukawa E, Higuchi S, et al. 1997. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J. Pharmacol. Exp. Ther. 283:1383-88
121. Meyer-Losic F, Nicolazzi C, Quinonero J, Ribes F, Michel M, et al. 2008. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin. Cancer Res. 14:2145-53
122. Hicks LD, Hyatt JL, Stoddard S, Tsurkan L, Edwards CC, et al. 2009. Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity. J. Med. Chem. 52:3742-52
123. Kuroda J, Kuratsu J, Yasunaga M, Koga Y, Kenmotsu H, et al. 2010. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab. Clin. Cancer Res. 16:521-29
124. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, et al. 2001. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7:2182-94
125. Ma MK, McLeod HL. 2003. Lessons learned from the irinotecan metabolic pathway. Curr. Med. Chem. 10:41-49
126. Chabot GG. 1995. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38. Cancer Chemother. Pharmacol. 36:463-72
127. Chabot GG. 1996. Clinical pharmacology and pharmacodynamics of irinotecan. A review. Ann. N. Y. Acad. Sci. 803:164-72
128. Scarpignato C, Hunt RH. 2010. Nonsteroidal antiinflammatory drug-related injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol. Clin. N. Am. 39:433-64
129. Bjarnason I. 2013. Gastrointestinal safety of NSAIDs and over-the-counter analgesics. Int. J. Clin. Pract. 67(Suppl. 178):37-42
130. Fortun PJ, Hawkey CJ. 2007. Nonsteroidal antiinflammatory drugs and the small intestine. Curr. Opin. Gastroenterol. 23:134-41
131. Maiden L. 2009. Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy. J. Gastroenterol. 44:64-71
132. Wallace JL. 2012. NSAID gastropathy and enteropathy: Distinct pathogenesis likely necessitates distinct prevention strategies. Br. J. Clin. Pharmacol. 165:67-74
133. Boelsterli UA, Redinbo MR, Saitta K. 2013. Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol. Sci. 131:654-67
134. Sarda S, Page C, Pickup K, Schulz-Utermoehl T, Wilson I. 2012. Diclofenac metabolism in the mouse: novel in vivo metabolites identified by high performance liquid chromatography coupled to linear ion trap mass spectrometry. Xenobiotica 42:179-94
135. Ju C, Uetrecht J. 1998. Oxidation of a metabolite of indomethacin (desmethyldeschlorobenzoylindomethacin) to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. Drug Metab. Dispos. 26:676-80
136. Kent TH, Cardelli RM, Stamler FW. 1969. Small intestinal ulcers and intestinal flora in rats given indomethacin. Am. J. Pathol. 54:237-48
137. Robert A, Asano T. 1977. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 14:333-41
138. Uejima M, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. 1996. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. Microbiol. Immunol. 40:553-60
139. Tannock GW, Savage DC. 1974. Influences of dietary and environmental stress on microbial populations in the murine gastrointestinal tract. Infect. Immun. 9:591-98
140. Reuter BK, Davies NM, Wallace JL. 1997. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology 112:109-17
141. Annadurai S, Guha-Thakurta A, Sa B, Dastidar SG, Ray R, Chakrabarty AN. 2002. Experimental studies on synergism between aminoglycosides and the antimicrobial antiinflammatory agent diclofenac sodium. J. Chemother. 14:47-53
142. Satoh H, Takeuchi K. 2012. Role of food and enterobacteria in the formation and prevention of small intestinal damage induced by NSAIDs. In Cell/Tissue Injury and Cytoprotection/Organoprotection in the Gastrointestinal Tract: Mechanisms, Prevention and Treatment, ed. LP Filaretova, K Takeuchi, pp. 52-60. Basel, Switz.: Karger
143. Stadnyk AW, Dollard C, Issekutz TB, Issekutz AC. 2002. Neutrophil migration into indomethacin induced rat small intestinal injury is CD11a/CD18 and CD11b/CD18 co-dependent. Gut 50:629-35
144. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, et al. 2008. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57:181-87
145. Cury DH, Costa JE, Irika K, Mijji L, Garcez A, et al. 2008. Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease. Dig. Dis. Sci. 53:2516-20
146. Fukumoto K, Naito Y, Takagi T, Yamada S, Horie R, et al. 2011. Role of tumor necrosis factor-α in the pathogenesis of indomethacin-induced small intestinal injury in mice. Int. J. Mol. Med. 27:353-59
147. Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K. 1999. Roles of enterobacteria, nitric oxide and neutrophil in the pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol. Res. 40:517-24
148. Vaishnava S, Yamamoto M, Severson KM, Ruhn KA, Yu X, et al. 2011. The antibacterial lectin RegIIIγ promotes the spatial segregation of microbiota and host in the intestine. Science 334:255-58
149. Geddes K, Philpot DJ. 2008. A new role for intestinal alkaline phosphatase in gut barrier maintenance. Gastroenterology 135:8-12
150. Qian D, Kinouchi T, Kunitoomo K, Kataoka K, Abdul Matin M, et al. 1993. Mutagenicity of the bile of dogs with an experimental model of an anomalous arrangement of the pancreaticobiliary duct. Carcinogenesis 14:743-47
151. Dabek M, McCrae SI, Stevens VJ, Duncan SH, Louis P. 2008. Distribution of β-glucosidase and β- glucuronidase activity and of β-glucuronidase gene gus in human colonic bacteria. FEMS Microbiol. Ecol. 66:487-95
152. Ilett KF, Tee LB, Reeves PT, Minchin RF. 1990. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol. Ther. 46:67-93
153. Haeberlin B, Rubas W, Nolen HW, Friend DR. 1993. In vitro evaluation of dexamethasone-β-Dglucuronide for colon-specific drug delivery. Pharm. Res. 10:1553-62
154. Wu B. 2012. Use of physiologically based pharmacokinetic models to evaluate the impact of intestinal glucuronide hydrolysis on the pharmacokinetics of aglycone. J. Pharm. Sci. 101:1281-301
155. Lanas A, Scarpignato C. 2006. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion 73(Suppl. 1):136-50
156. Montalto M, Gallo A, Gasbarrini A, Landolfi R. 2013. NSAID enteropathy: Could probiotics prevent it? J. Gastroenterol. 48:689-97
157. Guslandi M. 2012. Non-steroidal anti-inflammatory drugs-induced small intestinal injury and probiotic agents. World J. Gastroenterol. 18:4241-42
158. LoGuidice A, Wallace BD, Bendel L, Redinbo MR, Boelsterli UA. 2012. Pharmacologic targeting of bacterial β-glucuronidase alleviates nonsteroidal anti-inflammatory drug-induced enteropathy in mice. J. Pharmacol. Exp. Ther. 341:447-54
159. Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, Boelsterli UA. 2013. Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, ketoprofen or diclofenac: mode of action and pharmacokinetics. Xenobiotica. In press